Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,537–1,544 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Eli Lilly and Company Inluriyo (imlunestrant) - (EMBER-3) ER+/HER2– advanced or metastatic breast cancer (MBC) Phase 3 Data Released oral Oncology
Eli Lilly and Company Jaypirca (pirtobrutinib) - (BRUIN CLL-322) Chronic Lymphocytic Leukemia Phase 3 Ongoing Oral Oncology
Eli Lilly and Company Mounjaro (tirzepatide) - (SURPASS-CVOT) Type 2 diabetes and heart disease Phase 3 Data Released Subcutaneous Endocrinology
Eli Lilly and Company sofetabart mipitecan (LY4170156) Platinum-resistant ovarian cancer Phase 3 Ongoing oral Oncology
Eli Lilly and Company Tirzepatide (LY3298176) - (SURMOUNT-2) Obesity Phase 3 Data Released Subcutaneous Endocrinology
Eli Lilly and Company Mirikizumab Psoriasis Phase 3 Subcutaneous Immunology
Eli Lilly and Company Tibulizumab (ZB-106) - (TibuSURE) Systemic Sclerosis Phase 2 Enrollment Initiation Intravenous Immunology
Eli Lilly and Company JARDIANCE (empagliflozin) Heart failure with preserved ejection fraction (HFpEF) Phase 3 Oral Cardiology